ES2277745B1 - Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1. - Google Patents

Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1. Download PDF

Info

Publication number
ES2277745B1
ES2277745B1 ES200501431A ES200501431A ES2277745B1 ES 2277745 B1 ES2277745 B1 ES 2277745B1 ES 200501431 A ES200501431 A ES 200501431A ES 200501431 A ES200501431 A ES 200501431A ES 2277745 B1 ES2277745 B1 ES 2277745B1
Authority
ES
Spain
Prior art keywords
azabicyclo
octan
endo
chlorobenzyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200501431A
Other languages
English (en)
Spanish (es)
Other versions
ES2277745A1 (es
Inventor
Emma Terricabras Belart
Maria Dolors Fernandez Forner
Estrella Lozoya Toribio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Laboratorios Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200501431A priority Critical patent/ES2277745B1/es
Application filed by Laboratorios Almirall SA filed Critical Laboratorios Almirall SA
Priority to US11/921,961 priority patent/US20090130090A1/en
Priority to UY29572A priority patent/UY29572A1/es
Priority to ES06753965T priority patent/ES2332819T3/es
Priority to AT06753965T priority patent/ATE441647T1/de
Priority to EP06753965A priority patent/EP1891064B1/en
Priority to JP2008516161A priority patent/JP2008543795A/ja
Priority to PCT/EP2006/005129 priority patent/WO2006133802A1/en
Priority to CNA2006800266367A priority patent/CN101228158A/zh
Priority to DE602006008937T priority patent/DE602006008937D1/de
Priority to PE2006000656A priority patent/PE20070017A1/es
Priority to ARP060102442A priority patent/AR057651A1/es
Priority to TW095121003A priority patent/TW200716626A/zh
Publication of ES2277745A1 publication Critical patent/ES2277745A1/es
Application granted granted Critical
Publication of ES2277745B1 publication Critical patent/ES2277745B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
ES200501431A 2005-06-14 2005-06-14 Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1. Expired - Fee Related ES2277745B1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
ES200501431A ES2277745B1 (es) 2005-06-14 2005-06-14 Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
PCT/EP2006/005129 WO2006133802A1 (en) 2005-06-14 2006-05-30 N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists
ES06753965T ES2332819T3 (es) 2005-06-14 2006-05-30 Derivados n-amida de 8-azabiciclo(3.2.1.)oct-3-ilo como antagonistas de ccr1.
AT06753965T ATE441647T1 (de) 2005-06-14 2006-05-30 N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
EP06753965A EP1891064B1 (en) 2005-06-14 2006-05-30 N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists
JP2008516161A JP2008543795A (ja) 2005-06-14 2006-05-30 Ｃｃｒ１アンタゴニストとしての８−アザビシクロ［３．２．１］オクト−３−イルのｎ−アミド誘導体
US11/921,961 US20090130090A1 (en) 2005-06-14 2006-05-30 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists
CNA2006800266367A CN101228158A (zh) 2005-06-14 2006-05-30 作为ccr1拮抗剂的8-氮杂双环[3.2.1]辛-3-基的n-酰胺衍生物
DE602006008937T DE602006008937D1 (de) 2005-06-14 2006-05-30 N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
UY29572A UY29572A1 (es) 2005-06-14 2006-05-30 Derivados n-amida de 8-azabiciclo(3.2.1)oct-3-ilo como antagonistas del ccr1
PE2006000656A PE20070017A1 (es) 2005-06-14 2006-06-12 Derivados n-amida de 8-azabiciclo[3.2.1]oct-3-ilo como antagonistas de ccr1
ARP060102442A AR057651A1 (es) 2005-06-14 2006-06-12 Derivados n-amida de 8-azabiciclo[3.2.1]oct-3-ilo como antagonistas de ccr1, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas
TW095121003A TW200716626A (en) 2005-06-14 2006-06-13 N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as CCR1 antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200501431A ES2277745B1 (es) 2005-06-14 2005-06-14 Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.

Publications (2)

Publication Number Publication Date
ES2277745A1 ES2277745A1 (es) 2007-07-16
ES2277745B1 true ES2277745B1 (es) 2008-06-01

Family

ID=35740673

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200501431A Expired - Fee Related ES2277745B1 (es) 2005-06-14 2005-06-14 Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
ES06753965T Active ES2332819T3 (es) 2005-06-14 2006-05-30 Derivados n-amida de 8-azabiciclo(3.2.1.)oct-3-ilo como antagonistas de ccr1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06753965T Active ES2332819T3 (es) 2005-06-14 2006-05-30 Derivados n-amida de 8-azabiciclo(3.2.1.)oct-3-ilo como antagonistas de ccr1.

Country Status (12)

Country Link
US (1) US20090130090A1 (enExample)
EP (1) EP1891064B1 (enExample)
JP (1) JP2008543795A (enExample)
CN (1) CN101228158A (enExample)
AR (1) AR057651A1 (enExample)
AT (1) ATE441647T1 (enExample)
DE (1) DE602006008937D1 (enExample)
ES (2) ES2277745B1 (enExample)
PE (1) PE20070017A1 (enExample)
TW (1) TW200716626A (enExample)
UY (1) UY29572A1 (enExample)
WO (1) WO2006133802A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1994003A4 (en) * 2006-03-07 2009-12-02 Astrazeneca Ab PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEY
MX2010011154A (es) 2008-04-11 2010-12-21 Janssen Pharmaceutica Nv Tiazolopiridin-2-iloxi-fenilo y tiazolopirazin-2-iloxifenilaminas como moduladores de la leucotrieno a4 hidrolasa.
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
AU2010249041B2 (en) 2009-05-14 2014-11-13 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
WO2011087812A1 (en) * 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
JP6204983B2 (ja) * 2012-07-19 2017-09-27 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｃｒ２のオクタヒドロ−シクロペンタピロリル拮抗薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2003080574A1 (en) * 2002-03-25 2003-10-02 Astrazeneca Ab Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
WO2004099178A1 (en) * 2003-05-09 2004-11-18 Astrazeneca Ab Chemical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3633997A (en) * 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
AP2005003196A0 (en) * 2002-07-18 2005-03-31 Pfizer Prod Inc Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2003080574A1 (en) * 2002-03-25 2003-10-02 Astrazeneca Ab Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
WO2004099178A1 (en) * 2003-05-09 2004-11-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
PE20070017A1 (es) 2007-02-05
AR057651A1 (es) 2007-12-12
ES2277745A1 (es) 2007-07-16
ATE441647T1 (de) 2009-09-15
JP2008543795A (ja) 2008-12-04
UY29572A1 (es) 2006-12-29
EP1891064B1 (en) 2009-09-02
ES2332819T3 (es) 2010-02-12
EP1891064A1 (en) 2008-02-27
DE602006008937D1 (de) 2009-10-15
TW200716626A (en) 2007-05-01
CN101228158A (zh) 2008-07-23
WO2006133802A1 (en) 2006-12-21
US20090130090A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
DE60035204T2 (de) Tyrosinderivate
ES2315390T3 (es) Piperazinas sustituidas como moduladores del receptor de melanocortina.
ES2291448T3 (es) Derivados de urea como antagonistas de integrina alfa-4.
ES2321798T3 (es) Antagonistas del receptor de quimioquinas y metodos de uso para los mismos.
JP2003534343A (ja) 療法において有用なトロパン誘導体
JP4459622B2 (ja) ピペリジン誘導体およびケモカイン・レセプター（特にｃｃｒ５）活性モジュレーターとしてのその使用
JP2005503394A (ja) ケモカインレセプター活性の調節剤として有用なピペリジン誘導体
EP1263758A2 (en) 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
CN101712679B (zh) 一种酰胺类化合物、其药物组合物及其制备方法和用途
JP2008508241A (ja) アミノピペリジン誘導体、その調製及びメラノコルチン受容体作用物質としてのその使用
US7265146B2 (en) Integrin receptor inhibitors
TW200302096A (en) Chemical compounds
TW200305417A (en) Chemical compounds
JP2007513181A (ja) 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
ES2277745B1 (es) Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
CN101010320B (zh) 氨基托烷衍生物及其制备方法和治疗用途
ES2219177B1 (es) Derivados de n-(2-feniletil) sulfamida como antagonistas de la integrina alfa4.
KR19990044563A (ko) 신경이완제인 3베타-아미노 아자바이시클로 옥탄 또는 노난의 나프타미드 유도체
CA2590737A1 (en) Novel spirotropane compounds and methods for the modulation of chemokine receptor activity
US20050004163A1 (en) 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
AU2006235898A1 (en) 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20070716

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2277745B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180809